Apnimed has scored another phase 3 knockout. The Massachusetts biotech’s daily pill for obstructive sleep apnea reduced the ...

Apnimed, Inc., a pharmaceutical company advancing an industry-leading pipeline of first-in-class oral therapies that address the root causes of obstructive sleep apnea (OSA) and other sleep-related ...

The new pill, called AD109, is a combination of atomoxetine and aroxybutynin, two drugs that tell your brain to keep the ...

Moderate to severe OSA was associated with increased risk for severe and critical COVID-19, particularly in those with severe intermittent hypoxia.

An increased risk for comorbid insomnia and sleep apnea (COMISA) is significantly associated with reduced work ability.

Individuals with vs without knee, hip, or hand OA were associated with a significantly increased risk for sleep apnea.